|Bid||3.2800 x 900|
|Ask||4.0700 x 1800|
|Day's Range||3.3700 - 3.5300|
|52 Week Range||2.6400 - 16.2200|
|Beta (3Y Monthly)||1.90|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 3, 2017 - Aug 7, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.80|
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Allakos (NASDAQ: ALLK ) shares were up 112.6% ...
Shares of GlycoMimetics Inc. fell 53% in premarket trade Monday after the company announced Friday evening that a Phase 3 trial of a sickle-cell disease drug, developed in partnership with Pfizer Inc. , did not meet primary or secondary endpoints. Shares of Pfizer were down 0.8% in premarket trade on Monday. The drug, called rivipansel, is meant to treat vaso-occlusive crises (VOC), a common clinical manifestation of sickle-cell disease that occurs when sickled red blood cells irritate the lining of blood vessels and cause a painful inflammatory response that blocks those vessels. Such episodes can require hospitalization and are commonly treated with pain relievers like opioids and NSAIDs. Researchers were looking at whether rivipansel could shorten the time patients were hospitalized and decrease opioid consumption during treatment. "We are disappointed with the results, as we have been working in close partnership with the SCD community to advance rivipansel as a potential treatment option for acute VOC. We plan to share the study data at an upcoming scientific meeting as we want to ensure the learnings from this trial help inform future sickle cell programs that aim to improve care for SCD patients experiencing a VOC," said Brenda Cooperstone, Pfizer's chief development officer of rare disease. Shares of Pfizer have fallen 13% in the year to date through Friday, while GlycoMimetics stock has fallen 3.6%. The S&P 500 has gained 17%.
The company announces that rivipansel, which was developed in partnership with Pfizer, didn't meet primary or secondary endpoints.
GlycoMimetics, Inc. (GLYC) reported that Pfizer Inc. (PFE) announced today that the Phase 3 Rivipansel (GMI-1070): Evaluating Safety, Efficacy and Time to Discharge (RESET) pivotal study did not meet its primary or key secondary efficacy endpoints. The objective of the trial was to evaluate the efficacy and safety of rivipansel in patients aged six and older with sickle cell disease (SCD) who were hospitalized for a vaso-occlusive crisis (VOC) and required treatment with intravenous (IV) opioids. “We are both surprised and deeply disappointed by this outcome, as we had strongly hoped that rivipansel would have a positive benefit for people living with sickle cell disease,” said Rachel King, Chief Executive Officer of GlycoMimetics.
GlycoMimetics, Inc. announced today that it will host a conference call and webcast to report its second-quarter 2019 financial results on Thursday, August 1, 2019, at 8:30 a.m.
GlycoMimetics, Inc. today announced that Chief Executive Officer Rachel King will provide a corporate update at the Jefferies 2019 Healthcare Conference, on June 5 at 2:00 p.m.
How do you pick the next stock to invest in? One way would be to spend hours of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
GlycoMimetics, Inc. (GLYC) today announced that patient enrollment has been completed in the Phase 3 RESET (Rivipansel: Evaluating Safety, Efficacy and Time to Discharge) clinical trial, which is evaluating the efficacy and safety of rivipansel for the acute treatment of vaso-occlusive crisis (VOC) in sickle cell disease (SCD). In 2011, GlycoMimetics and Pfizer Inc. (PFE) entered into a worldwide license agreement for the development and, if approved by applicable regulatory authorities, commercialization of rivipansel. Since completion of the Phase 2 clinical trial, Pfizer, has been responsible for clinical development of rivipansel, including the RESET clinical trial.
On a per-share basis, the Rockville, Maryland-based company said it had a loss of 33 cents. The results topped Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment ...
ROCKVILLE, Md.-- -- Enrolled first patient in National Cancer Institute -sponsored Phase 3 trial of uproleselan in older adults with previously untreated acute myeloid leukemia Announced plans to initiate a trial of GMI-1359 in individuals with breast cancer in collaboration with the Duke Cancer Institute Established transition plan to new Chairman of Board of Directors GlycoMimetics, Inc. today reported ...
NEW YORK, NY / ACCESSWIRE / May 2, 2019 / GlycoMimetics, Inc. (NASDAQ: GLYC ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 2, 2019 at 8:30 AM Eastern ...
GlycoMimetics, Inc. (GLYC) today announced the addition of two senior executives to its executive management team. Eric Feldman, M.D., a specialist in leukemia and bone marrow disorder therapies, has been appointed Vice President of Clinical Development. Christian Dinneen-Long, an attorney with deep experience in the biotechnology industry, has been appointed Vice President and Corporate Counsel.
GlycoMimetics, Inc. announced today that it will host a conference call and webcast to report its first-quarter 2019 financial results on Thursday, May 2, 2019, at 8:30 a.m.
GlycoMimetics, Inc. (GLYC) announced today dosing of the first patient in a Phase 3 clinical trial being conducted under the auspices of a Cooperative Research and Development Agreement (CRADA) between GlycoMimetics and the National Cancer Institute (NCI), part of the National Institutes of Health. The second in a series of trials designed to evaluate uproleselan across the continuum of care in AML, this NCI-sponsored study is evaluating the addition of uproleselan to a standard cytarabine/daunorubicin regimen (7&3) in older adults with previously untreated AML who are suitable for intensive chemotherapy.
Data shows that E-selectin is key to tumor growth and metastasis to bone and provides further support for upcoming clinical trial in patients with metastatic breast cancer
GlycoMimetics, Inc. (GLYC) today announced plans to initiate a clinical trial of GMI-1359 in breast cancer patients whose tumors have spread to bone. GMI-1359 is a dual function antagonist that targets both E-selectin and CXCR4, both of which are involved in tumor trafficking and metastatic spread.
GlycoMimetics, Inc. today announced that senior management will present corporate updates at two upcoming investor conferences in April. Details are as follows: